Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

5,350-average patient population with advanced NSCLC Exon-20 in the US. That includes ~1630 w the EGFR mutation and ~3744 with the HER2 mutation. That's because only around 10% of advanced EGFR NSCLC pts has the Exon 20 mutation while ~96% of advanced HER2 NSCLC pts has the Exon 20 mutation. That's interesting. Also, the EU has almost double the patient cases than the US, ~ 9400 vs 5350. 9400 cases in the EU should generate strong interest from big pharma for a EU licensing deal. We, as investors, may not get to hear about the data till an ASCO or other meeting takes place but Spectrum has that data in hand and could show it to any pharma that has an interest in licensing the product in the EU. Of course they'll sign a Non-Disclosure Agreement to see the data.